Last €164.29 EUR
Change Today +2.29 / 1.42%
Volume 510.0
AXPM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 9:01 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (AXPM) Snapshot

Open
€162.60
Previous Close
€162.00
Day High
€168.85
Day Low
€160.63
52 Week High
03/2/15 - €168.85
52 Week Low
04/14/14 - €99.44
Market Cap
33.2B
Average Volume 10 Days
299.7
EPS TTM
--
Shares Outstanding
202.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXION PHARMACEUTICALS INC (AXPM)

alexion pharmaceuticals inc (AXPM) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (AXPM) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

2,273 Employees
Last Reported Date: 02/6/15
Founded in 1992

alexion pharmaceuticals inc (AXPM) Top Compensated Officers

Co-Founder, Chairman of the Board and Chief E...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $615.0K
Chief Operating Officer and Director
Total Annual Compensation: $610.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $547.0K
Chief Strategy & Portfolio Officer and Execut...
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2013.

alexion pharmaceuticals inc (AXPM) Key Developments

Alexion Receives CHMP Positive Opinions for Important Updates to the EU Label for Soliris (eculizumab)

Alexion announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a Positive Opinion to update the therapeutic indication for Soliris (eculizumab) in the treatment of paroxysmal nocturnal haemoglobinuria (PNH) for patients with high disease activity regardless of history of transfusion. The CHMP also issued a Positive Opinion to update the EU label for Soliris with additional data on the benefits of long-term treatment and the risks associated with treatment discontinuation in patients with atypical haemolytic uremic syndrome (aHUS). If approval is granted, updated information for the use of Soliris in both PNH and aHUS will be detailed in the Summary of Product Characteristics (SmPC) which will be published in the revised European Public Assessment Report (EPAR).

Alexion Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Alexion Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

Alexion Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 03:30 PM

Alexion Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 03:30 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AXPM:GR €164.29 EUR +2.29

AXPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,387 INR +37.60
Regeneron Pharmaceuticals Inc $417.02 USD +3.18
Sigma-Aldrich Corp $138.09 USD +0.03
Symrise AG €56.72 EUR +0.048
United Therapeutics Corp $155.39 USD +0.34
View Industry Companies
 

Industry Analysis

AXPM

Industry Average

Valuation AXPM Industry Range
Price/Earnings 55.4x
Price/Sales 16.0x
Price/Book 10.9x
Price/Cash Flow 55.5x
TEV/Sales 15.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit www.alexionpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.